NEK2 and prostate cancer: More important, a large number of studies showed that NEK2 overexpression occurred in many human solid tumors, including hepatocellular carcinoma (HCC) [10–16], colorectal cancer (CRC) [17–19], pancreatic ductal cancer [20], lung cancer [21,22], prostate cancer [23], breast carcinoma [24], and glioma [25,26].